AMGN vs GILD
AMGN and GILD side by side — valuation & fundamentals (public data).
Key statistics
| Metric | AMGNAmgen Inc. | GILDGILEAD SCIENCES, INC. |
|---|---|---|
| Market cap | $232.35B | $181.46B |
| P/E (TTM) | 26.7 | 21.6 |
| P/B | 19.88 | 15.34 |
| P/S | 6.3x | 6.2x |
| Dividend yield | 2.21% | 2.21% |
| Revenue | $38.09B(TTM) | $30.46B(TTM) |
| Revenue growth (YoY) | 10.0% | 2.4% |
| Net income | $8.74B(TTM) | -$3.24B(TTM) |
| Earnings growth (YoY) | 88.5% | 1672.9% |
| EPS, diluted | $16.10(TTM) | $-2.65(TTM) |
| EBIT margin | 24.7% | 34.0% |
| ROE | 66.0% | 71.9% |
| ROIC | 15.1% | 26.7% |
| 1y total return | +52.7% | +32.4% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: AMGN vs GILD
| Metric | AMGN | GILD |
|---|---|---|
| End value | $36.5K | $21.6K |
| Total return | +265.3% | +116.2% |
| CAGR | +13.3% | +7.7% |
| Volatility | 24.8% | 25.7% |
| Sharpe | 0.47 | 0.27 |
| Sortino | 0.70 | 0.39 |
| Max drawdown | -24.9% | -32.5% |
Based on 2600 common trading days, 2016-04-28 → 2026-08-31 · risk-free 3.9% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)